HK 006
Alternative Names: HK-006Latest Information Update: 06 Jun 2022
At a glance
- Originator Hefei HankeMab Biotechnology
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 30 May 2022 Preclinical trials in Cancer in China (Parenteral) prior to May 2022 (Hefei HankeMab Biotechnology pipeline, May 2022)
- 30 May 2022 Adverse events and pharmacodynamics data from a preclinical studies in Cancer released by Hefei HankeMab Biotechnology (Hefei HankeMab Biotechnology pipeline, May 2022)